Drug Type Small molecule drug |
Synonyms AZD 9056, AZD9056, MP-118 + [1] |
Target |
Action antagonists |
Mechanism P2X7 receptor antagonists(P2X purinoceptor 7 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H35ClN2O2 |
InChIKeyHSQAARMBHJCUOK-UHFFFAOYSA-N |
CAS Registry345304-65-6 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Rheumatoid Arthritis | Phase 2 | United States | 01 Aug 2007 | |
| Rheumatoid Arthritis | Phase 2 | Argentina | 01 Aug 2007 | |
| Rheumatoid Arthritis | Phase 2 | Australia | 01 Aug 2007 | |
| Rheumatoid Arthritis | Phase 2 | Belgium | 01 Aug 2007 | |
| Rheumatoid Arthritis | Phase 2 | Canada | 01 Aug 2007 | |
| Rheumatoid Arthritis | Phase 2 | Czechia | 01 Aug 2007 | |
| Rheumatoid Arthritis | Phase 2 | France | 01 Aug 2007 | |
| Rheumatoid Arthritis | Phase 2 | Mexico | 01 Aug 2007 | |
| Rheumatoid Arthritis | Phase 2 | Poland | 01 Aug 2007 | |
| Rheumatoid Arthritis | Phase 2 | Romania | 01 Aug 2007 |
Phase 2 | 383 | kbbwvkqjdl(fafeqbijbk) = cwoxdkcfie uwbtnnhudt (srbpvbvflk ) | Negative | 01 Oct 2012 | |||
Placebo | kbbwvkqjdl(fafeqbijbk) = ylaavxbmot uwbtnnhudt (srbpvbvflk ) | ||||||
Phase 2 | 385 | (AZD9056 50 mg) | msgnntzgsh = jpqrybbqis kvusmscfxi (fuatdarpaf, uosekxpret - drynoftjkw) View more | - | 04 Oct 2010 | ||
(AZD9056 100 mg) | msgnntzgsh = xgjqeknvyr kvusmscfxi (fuatdarpaf, hwqbyhrwfh - qlpxafqvyx) View more | ||||||
Phase 2 | 75 | AZD9056 100 mg | xmcgreuczg(svedjybxnc) = ayiimddpuj oyjfvesmhx (zoorsrskqj ) | Positive | 10 Jun 2009 | ||
xmcgreuczg(svedjybxnc) = hdmxopnwdy oyjfvesmhx (zoorsrskqj ) |





